JG
TGTX icon

Jefferies Group’s TG Therapeutics TGTX Stock Holding History

Jefferies Group’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-10,664
Closed -$86K – 2860
2019
Q1 		$86K Sell
10,664
-24,316
-70% -$131K ﹤0.01% 2142
2018
Q4 		$143K Buy
34,980
+16,380
+88% +$81.4K ﹤0.01% 1910
2018
Q3 		$104K Buy
18,600
+13,800
+288% +$158K ﹤0.01% 2219
2018
Q2 		$63K Buy
+4,800
New +$66K ﹤0.01% 2188
2015
Q3 		– Sell
-88
Closed -$1K – 3000
2015
Q2 		$1K Buy
+88
New +$1.39K ﹤0.01% 3224

Other funds holding TGTX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jefferies Group's TGTX Position: Q2 2019 in Review

Jefferies Group sold out of TG Therapeutics (TGTX) in Q2 2019, closing a stake of 10,664 shares — an estimated $86K sold.

Jefferies Group first reported a position in TGTX in Q2 2015 and held it in 5 quarters. The position peaked at $143K in Q4 2018. 116 funds tracked by Wall St. Rank hold TGTX as of Q2 2019.

  • Jefferies Group reported no remaining TG Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Jefferies Group sold 10,664 TG Therapeutics shares in Q2 2019, an estimated $86K.
  • Jefferies Group first reported a position in TG Therapeutics in Q2 2015 and held it in 5 quarters.
  • Jefferies Group's TG Therapeutics position peaked at $143K in Q4 2018.
  • 116 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2019.

Based on Jefferies Group's 13F filing for Q2 2019, filed 14 Aug 2019.